New research from CorriXR Therapeutics has demonstrated a promising gene-editing technique that could potentially restore the effectiveness of chemotherapy in patients with aggressive cancers that have developed resistance to treatment. The study, published in Molecular Therapy Oncology, reveals how manipulating the NRF2 transcription factor can reactivate chemosensitivity in models of head and neck and esophageal squamous cell carcinoma.
The collaborative study involved scientists from the ChristianaCare Gene Editing Institute and builds on existing data related to lung cancer. Researchers employed CRISPR/Cas9 technology to disrupt NRF2, a key player in cellular stress responses and a known contributor to chemotherapy resistance. This innovative approach targets tumor cells’ protective mechanisms, thereby enhancing their vulnerability to standard chemotherapy drugs.
“For patients with solid tumors, once chemotherapy resistance sets in, options narrow quickly and often become more toxic,” stated Eric B. Kmiec, founder and CEO of CorriXR Therapeutics. He emphasized that the data indicates precise disruption of NRF2 could revitalize traditional treatments, potentially enabling doctors to administer lower doses while improving disease management and minimizing side effects.
Researchers conducted their experiments by editing NRF2 in hypopharyngeal and esophageal squamous cell carcinoma cell lines. They assessed gene-editing efficiency, pathway activity, and responses to established chemotherapy agents like cisplatin and 5-fluorouracil. The results showed a significant reduction in NRF2 protein levels, suppression of downstream stress-response genes, and a notable restoration of sensitivity to chemotherapy. These enhanced responses persisted, creating what researchers described as a renewed window for effective combination therapy.
Importantly, the study also established that targeting specific functional domains of NRF2 can neutralize its activity, regardless of the underlying genetic mutations present in cancer cells. This broadens the potential application of this therapy across various tumor types. “These findings reinforce NRF2 as a central node in drug resistance,” remarked Natalia Rivera-Torres, lead author of the study and associate director of research at the ChristianaCare Gene Editing Institute. The results complement prior data indicating that tumor-specific NRF2 editing could resensitize cancers to chemotherapy and inhibit tumor growth in vivo.
CorriXR Therapeutics is advancing its investigational studies to support a new drug application for head and neck squamous cell carcinoma, which accounts for about 90% of head and neck cancer cases. This type of cancer ranks as the world’s seventh most diagnosed cancer, with global incidence projected to reach one million new cases annually by 2030. Alarmingly, approximately half of patients experience a recurrence within two years, highlighting the urgent need for novel strategies to overcome treatment resistance.
The company plans to finalize additional in vivo studies combining NRF2 editing with chemotherapy and radiation treatments in the first half of 2026. CorriXR is dedicated to developing non-viral genetic medicines that target NRF2, aiming to resensitize tumors to standard therapies, whether used alone or in conjunction with chemotherapy, radiotherapy, or immunotherapy.
For further details, visit www.corrixr.com and www.geneeditinginstitute.com. The ChristianaCare Gene Editing Institute, established in 2015 within the Helen F. Graham Cancer Center & Research Institute, continues to serve as a research hub for gene-editing technologies and played a crucial role in the formation of CorriXR Therapeutics.
